



Caring Ambassadors Lung Cancer Program

Literature Review, July 2016

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES	1-4
SCREENING, DIAGNOSIS AND STAGING	4-8
CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES	
NSCLC SURGERY	8-13
NSCLC IMMUNOTHERAPY	13-14
NSCLC CHEMOTHERAPY	14-19
NSCLC RADIOTHERAPY	19-22
SMALL CELL LUNG CANCER (SCLC)	22-26
PALLIATIVE AND SUPPORTIVE CARE	26-27
COMPLEMENTARY AND ALTERNATIVE THERAPY	27
MISCELLANEOUS WORKS	28-30

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

[Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.](#) Liu M1, Wang H2, Liu L3, Wang B4, Sun G5. J Transl Med. 2016 Jun 1;14(1):155. doi: 10.1186/s12967-016-0910-0.

[miRNA-124 modulates lung carcinoma cell migration and invasion.](#) Li Z, Wang X, Li W, Wu L, Chang L, Chen H. Int J Clin Pharmacol Ther. 2016 Jun 1. [Epub ahead of print]

[A combinatorial strategy for treating KRAS-mutant lung cancer.](#) Manchado E1, Weissmueller S1,2, Morris JP1, et al. Nature. 2016 Jun 22;534(7609):647-651. doi: 10.1038/nature18600. [Epub ahead of print]

[Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.](#) DiBardino DM1, Saqi A2, Elvin JA3, Greenbowe J3, Suh JH3, Miller VA3, Ali SM3, Stoopler M4, Bulman WA5. Clin Lung Cancer. 2016 Jun 8. pii: S1525-7304(16)30133-4. doi: 10.1016/j.clcc.2016.05.017. [Epub ahead of print]

[Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.](#) Zhang H1, Shao H2, Golubovskaya VM3, Chen H1, Cance W3, Adjei AA1, Dy GK1. Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.190. [Epub ahead of print]

[Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer.](#) Singhal S1, Bhojnagarwala PS2, O'Brien S3, et al. Cancer Cell. 2016 Jun 30. pii: S1535-6108(16)30226-4. doi: 10.1016/j.ccell.2016.06.001. [Epub ahead of print]

[Impact of Staging With Positron-emission Tomography \(PET\) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.](#) Raghunathan R1, Cease K, Troeschel S, Zhao L, Gross M, Chen G, Chopra V, Ramnath N. Am J Clin Oncol. 2016 Jun 17. [Epub ahead of print]

[Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples.](#) Sanders H1, Qu K2, Li H2, et al. Mol Diagn Ther. 2016 Jun;20(3):241-53. doi: 10.1007/s40291-016-0197-0.

[Safety and feasibility of prolonged bronchoscopy involving diagnosis of lung cancer, systematic nodal staging, and fiducial marker placement in a high-risk population.](#) Kular H1, Mudambi L1, Lazarus DR1, Cornwell L1, Zhu A1, Casal RF1. J Thorac Dis. 2016 Jun;8(6):1132-8. doi: 10.21037/jtd.2016.04.06.

[Perceptions and utilization of lung cancer screening among primary care physicians.](#) Raz DJ1, Wu GX1, Consunji M1, et al. J Thorac Oncol. 2016 Jun 23. pii: S1556-0864(16)30527-5. doi: 10.1016/j.jtho.2016.06.010. [Epub ahead of print]

[Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer.](#) Robles AI1, Harris CC2. Lung Cancer. 2016 Jun 14. pii: S0169-5002(16)30361-0. doi: 10.1016/j.lungcan.2016.06.003. [Epub ahead of print]

[Comprehensive clinical staging for resectable lung cancer: Clinico-pathological correlations and the role of brain MRI.](#) Vernon J1, Andruszkiewicz N2, Schneider L1, Schieman C1, Finley CJ1, Shargall Y1, Fahim C1, Farrokhyar F2, Hanna WC3. J Thorac Oncol. 2016 Jun 22. pii: S1556-0864(16)30520-2. doi: 10.1016/j.jtho.2016.06.003. [Epub ahead of print]

[Validation of an Electronic Program for Pathologist Training in the Interpretation of a Complex Companion Diagnostic Immunohistochemical Assay.](#) Dennis E1, Banks P2, Murata LB2, et al. Hum Pathol. 2016 Jun 24. pii: S0046-8177(16)30131-9. doi: 10.1016/j.humpath.2016.06.013. [Epub ahead of print]

[Knowledge of, attitudes toward, and use of low-dose computed tomography for lung cancer screening among family physicians.](#) Ersek JL1,2, Eberth JM1,3, McDonnell KK4, Strayer SM5, Sercy E3, Cartmell KB6, Friedman DB3,7. Cancer. 2016 Jun 13. doi: 10.1002/cncr.29944. [Epub ahead of print]

[Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma.](#) Makino T1, Mikami T2, Hata Y1, et al. Ann Thorac Surg. 2016 Jun 28. pii: S0003-4975(16)30481-7. doi: 10.1016/j.athoracsur.2016.04.100. [Epub ahead of print]

NSCLC - SURGERY

[Smoking status and 30-day mortality in patients undergoing pulmonary resections.](#) Mediratta N1, Poullis M2. Asian Cardiovasc Thorac Ann. 2016 Jun 30. pii: 0218492316657252. [Epub ahead of print]

[Comparison of treatment outcomes between single-port video-assisted thoracoscopic anatomic segmentectomy and lobectomy for non-small cell lung cancer of early-stage: a retrospective observational study.](#) Lin Y1, Zheng W1, Zhu Y1, Guo Z1, Zheng B1, Chen C1. J Thorac Dis. 2016 Jun;8(6):1290-6. doi: 10.21037/jtd.2016.04.65.

[For non-small cell lung cancer with T3 \(central\) disease, sleeve lobectomy or pneumonectomy?](#) Ma QL1, Guo YQ1, Shi B1, Tian YC1, Song ZY1, Liu DR1. J Thorac Dis. 2016 Jun;8(6):1227-33. doi: 10.21037/jtd.2016.04.60.

[Physiologic assessment before video thoracoscopic resection for lung cancer in patients with abnormal pulmonary function.](#) Benattia A1, Debeaumont D1, Guyader V1, Tardif C1, Peillon C1, Cuvelier A1, Baste JM1. J Thorac Dis. 2016 Jun;8(6):1170-8. doi: 10.21037/jtd.2016.04.38.

[Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer.](#) Johnson KK1, Rosen JE1, Salazar MC1, Boffa DJ2. Ann Thorac Surg. 2016 Jun 23. pii: S0003-4975(16)30418-0. doi: 10.1016/j.athoracsur.2016.04.086. [Epub ahead of print]

[The Outcomes of a Limited Resection for Non-Small Cell Lung Cancer Based on Differences in Pathology.](#) Yano M1, Yoshida J2, Koike T3, et al. World J Surg. 2016 Jun 30. [Epub ahead of print]

[Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer.](#) Brown LM1, Louie BE2, Jackson N3, Farivar AS4, Aye RW4, Vallières E4. Ann Thorac Surg. 2016 Jun 24. pii: S0003-4975(16)30367-8. doi: 10.1016/j.athoracsur.2016.04.037. [Epub ahead of print]

[Detection of Recurrence Patterns After Wedge Resection for Early Stage Lung Cancer: Rationale for Radiologic Follow-Up.](#) Billè A1, Ahmad U2, Woo KM3, Suzuki K2, Adusumilli P2, Huang J2, Jones DR2, Rizk NP2. Ann Thorac Surg. 2016 Jun 24. pii: S0003-4975(16)30386-1. doi: 10.1016/j.athoracsur.2016.04.056. [Epub ahead of print]

[Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.](#) Nishii T1,2, Yokose T2, Miyagi Y3, et al. Asia Pac J Clin Oncol. 2016 Jun 28. doi: 10.1111/ajco.12512. [Epub ahead of print]

[Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.](#) Takada K1, Okamoto T2, Shoji F3, et al. J Thorac Oncol. 2016 Jun 23. pii: S1556-0864(16)30523-8. doi: 10.1016/j.jtho.2016.06.006. [Epub ahead of print]

NSCLC - IMMUNOTHERAPY

[Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.](#)

Gettinger S1, Rizvi NA2, Chow LQ2, et al. J Clin Oncol. 2016 Jun 27. pii: JCO669929. [Epub ahead of print]

[**Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.**](#) Rizvi NA1, Hellmann MD2, Brahmer JR2, et al. J Clin Oncol. 2016 Jun 27. pii: JCO669861. [Epub ahead of print]

NSCLC - CHEMOTHERAPY

[**Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.**](#) Suzuki S1, Karayama M1,2, Inui N3,4, et al. Invest New Drugs. 2016 Aug;34(4):490-6. doi: 10.1007/s10637-016-0365-4. Epub 2016 Jun 9.

[**Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma.**](#) Yoshiya T1, Mimae T1, Tsutani Y1, et al. Ann Thorac Surg. 2016 Jun 23. pii: S0003-4975(16)30419-2. doi: 10.1016/j.athoracsur.2016.04.087. [Epub ahead of print]

[**Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer.**](#) Deek MP1, Kim S, Ahmed I, Fang BS, Zou W, Malhotra J, Aisner J, Jabbour SK. Am J Clin Oncol. 2016 Jun 17. [Epub ahead of print]

[**Brain metastases from non-small cell lung cancer: radiation therapy in the era of targeted therapies.**](#)

Khalifa J1, Amini A2, Popat S3, Gaspar LE2, Faivre-Finn C4; IASLC Advanced Radiation Technology Committee. J Thorac Oncol. 2016 Jun 22. pii: S1556-0864(16)30519-6. doi: 10.1016/j.jtho.2016.06.002. [Epub ahead of print]

Initial data available to date and discuss future directions to improve outcome in this group of patients.

[**Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.**](#) Yoshida T1, Oya Y2, Tanaka K2, et al. J Clin Oncol. 2016 Jun 27. pii: JCO658732. [Epub ahead of print]

[**Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC.**](#) Zhang YC1,2, Zhou Q2, Wu YL2. Expert Opin Pharmacother. 2016 Jun 30. [Epub ahead of print]

[**Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials.**](#) Bilen MA1, Patel A2, Hess KR3, et al. Cancer Chemother Pharmacol. 2016 Jul;78(1):167-71. doi: 10.1007/s00280-016-3073-z. Epub 2016 Jun 10.

[**Safety of gefitinib in non-small cell lung cancer treatment.**](#) Hsiue EH1, Lee JH1,2,3,4, Lin CC1,3,4, Yang JC1,2,3,4. Expert Opin Drug Saf. 2016 Jul;15(7):993-1000. doi: 10.1080/14740338.2016.1192605. Epub 2016 Jun 7.

[**A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial.**](#) Yanagita M1, Redig AJ1, Paweletz CP2, et al. Clin Cancer Res. 2016 Jun 8. pii: clincanres.0909.2016. [Epub ahead of print]

[Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer.](#) Wang E1, Nickens DJ2, Bello A3, Khosravan R4, Amantea M5, Wilner K6, Parivar K7, Tan W8. Clin Cancer Res. 2016 Jun 8. pii: clincanres.0536.2016. [Epub ahead of print]

[Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.](#) Yang KL1, Chang YC2, Ko HL3, et al. Clin Lung Cancer. 2016 Jun 8. pii: S1525-7304(16)30129-2. doi: 10.1016/j.clcc.2016.05.013. [Epub ahead of print]

NSCLC - RADIOTHERAPY

[Characterizing spatiotemporal information loss in sparse-sampling-based dynamic MRI for monitoring respiration-induced tumor motion in radiotherapy.](#) Arai TJ1, Nofiele J2, Madhuranthakam AJ3, Yuan Q2, Pedrosa I3, Chopra R3, Sawant A4. Med Phys. 2016 Jun;43(6):2807. doi: 10.1118/1.4948684.

[Hypofractionated Intensity-Modulated Radiotherapy for Patients With Non-Small-Cell Lung Cancer.](#) Pollom EL1, Qian Y1, Durkee BY1, et al. Clin Lung Cancer. 2016 Jun 8. pii: S1525-7304(16)30140-1. doi: 10.1016/j.clcc.2016.05.024. [Epub ahead of print]

[Patterns of loco-regional relapses in contemporarily staged stage III-N2 non-small cell lung cancer patients treated with induction chemotherapy and resection: Implications for postoperative radiotherapy target volumes.](#) Billiet C1, De Ruysscher D2, Peeters S3, et al. J Thorac Oncol. 2016 Jun 30. pii: S1556-0864(16)30589-5. doi: 10.1016/j.jtho.2016.05.037. [Epub ahead of print]

[Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy \(SABR\).](#) Chaudhuri AA1, Binkley MS1, Rigdon J2, et al. Radiother Oncol. 2016 Jun;119(3):454-60. doi: 10.1016/j.radonc.2016.05.007. Epub 2016 Jun 3.

[Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.](#) Campo M1, Al-Halabi H2, Khandekar M2, Shaw AT3, Sequist LV3, Willers H4. Oncologist. 2016 Jun 27. pii: theoncologist.2015-0508. [Epub ahead of print]

[Cost of Intensity-modulated Radiation Therapy for Older Stage III Lung Cancer Patients.](#) Kale MS1, Mhango G2, Bonomi M3, Federman A4, Sigel K5, Rosenzweig KE6, Wisnivesky JP7. Ann Am Thorac Soc. 2016 Jun 14. [Epub ahead of print]

SMALL CELL LUNG CANCER - SCLC

[PD-L1 and c-MET expression and survival in patients with small cell lung cancer.](#) Miao L1, Lu Y1, Xu Y1, Zhang G2, Huang Z1, Gong L1, Fan Y1. Oncotarget. 2016 Jun 1. doi: 10.18632/oncotarget.9765. [Epub ahead of print]

[Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer.](#) Fernandez-Cuesta L1, Perdomo S2, Avogbe PH1, et al. EBioMedicine. 2016 Jun 25. pii: S2352-3964(16)30289-4. doi: 10.1016/j.ebiom.2016.06.032. [Epub ahead of print]

[Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.](#)

Jahchan NS1, Lim JS1, Bola B2, et al. Cell Rep. 2016 Jun 29. pii: S2211-1247(16)30761-6. doi: 10.1016/j.celrep.2016.06.021. [Epub ahead of print]

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Goto K1, Ohe Y2, Shibata T3, et al. Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30104-8. doi: 10.1016/S1470-2045(16)30104-8. [Epub ahead of print]

The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. Horn L1, Reck M2, Spigel DR3. Oncologist. 2016 Jun 27. pii: theoncologist.2015-0523. [Epub ahead of print]

Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. Jahchan NS1, Lim JS1, Bola B2, et al. Cell Rep. 2016 Jun 29. pii: S2211-1247(16)30761-6. doi: 10.1016/j.celrep.2016.06.021. [Epub ahead of print]

Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients. Hatfield LA1, Huskamp HA2, Lamont EB2. Oncol Pract. 2016 Jun 28. pii: JOPR012492. [Epub ahead of print]

Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer. Arriola E1, Wheeler M2, Galea I3, et al. J Thorac Oncol. 2016 Jun 10. pii: S1556-0864(16)30503-2. doi: 10.1016/j.jtho.2016.05.028. [Epub ahead of print]

PALLIATIVE AND SUPPORTIVE CARE

Predictors of psychological distress in advanced cancer patients under palliative treatments. Diaz-Frutos D1,2,3, Baca-Garcia E1, García-Foncillas J2, López-Castroman J1,4. Eur J Cancer Care (Engl). 2016 Jul;25(4):608-15. doi: 10.1111/ecc.12521. Epub 2016 Jun 8.

Early and Intensive Dietary Counseling in Lung Cancer Patients Receiving (Chemo)Radiotherapy- A Pilot Randomized Controlled Trial. Kiss N1,2,3, Isenring E4,5, Gough K1, et al. Nutr Cancer. 2016 Jun 27:1-10. [Epub ahead of print]

Evaluation of sarcopenia in small-cell lung cancer patients by routine chest CT. Kim EY1, Kim YS2, Park I3, Ahn HK3, Cho EK3, Jeong YM1, Kim JH1. Support Care Cancer. 2016 Jun 30. [Epub ahead of print]

COMPLEMENTARY & ALTERNATIVE THERAPY

Moringa oleifera's Nutritious Aqueous Leaf Extract Has Anticancerous Effects by Compromising Mitochondrial Viability in an ROS-Dependent Manner. Madi N1, Dany M2, Abdoun S3, Usta J1. J Am Coll Nutr. 2016 Jun 17:1-10. [Epub ahead of print]

MISCELLANEOUS WORKS

[**Racial/Ethnic Disparities in Genomic Sequencing.**](#) Spratt DE1, Chan T2, Waldron L2, Speers C1, Feng FY1, Ogunwobi OO3, Osborne JR4. JAMA Oncol. 2016 Jun 30. doi: 10.1001/jamaoncol.2016.1854. [Epub ahead of print]

[**Beyond Traditional Newspaper Advertisement: Leveraging Facebook-Targeted Advertisement to Recruit Long-Term Smokers for Research.**](#) Carter-Harris L1, Bartlett Ellis R, Warrick A, Rawl S. J Med Internet Res. 2016 Jun 15;18(6):e117. doi: 10.2196/jmir.5502.

[**Impact of Race on Treatment and Survival among U.S. Veterans with Early-Stage Lung Cancer.**](#) Williams CD1, Salama JK2, Moghanaki D3, Karas TZ4, Kelley MJ5. J Thorac Oncol. 2016 Jun 10. pii: S1556-0864(16)30505-6. doi: 10.1016/j.jtho.2016.05.030. [Epub ahead of print]

[**Cancer survivors' experiences with insurance, finances, and employment: results from a multisite study.**](#) Nekhlyudov L1, Walker R2, Ziebell R2, Rabin B3,4,5, Nutt S6,7, Chubak J2. J Cancer Surviv. 2016 Jun 9. [Epub ahead of print]